73.00
price up icon1.64%   1.18
after-market Handel nachbörslich: 73.11 0.11 +0.15%
loading

Astrazeneca PLC Aktie (AZN) Neueste Nachrichten

pulisher
09:55 AM

AstraZeneca (AZN) Veteran Joins Perrigo Leadership Team | AZN St - GuruFocus

09:55 AM
pulisher
08:22 AM

Hydrogel-based Drug Delivery System Market Top Companies Study - openPR.com

08:22 AM
pulisher
05:21 AM

Transcript : AstraZeneca PLC Presents at American Society of Clinical Oncology Annual Meeting 2025, Jun-02-2025 - marketscreener.com

05:21 AM
pulisher
Jun 03, 2025

AZN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies AstraZeneca PLC Shareholders of Class Action and Encourages Shareholders to Contact the Firm - ACCESS Newswire

Jun 03, 2025
pulisher
Jun 03, 2025

AstraZeneca (LSE:AZN) Reports Positive Trial Results For ENHERTU® In Breast Cancer Treatment - Yahoo

Jun 03, 2025
pulisher
Jun 03, 2025

M42 Partners with AstraZeneca, Sophia Genetics for Liquid Biopsy Testing in UAE - marketscreener.com

Jun 03, 2025
pulisher
Jun 03, 2025

AstraZeneca: Enhertu promising against breast cancer - marketscreener.com

Jun 03, 2025
pulisher
Jun 02, 2025

AstraZeneca (AZN) Reports Promising Phase 3 Results for Enhertu and Perjeta Combo - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Astrazeneca (AZN) Stock Declines While Market Improves: Some Information for Investors - Nasdaq

Jun 02, 2025
pulisher
Jun 02, 2025

AstraZeneca says Enhertu, Perjeta combo cuts death risk in breast cancer (AZN:NASDAQ) - Seeking Alpha

Jun 02, 2025
pulisher
Jun 02, 2025

AstraZeneca (AZN) Considered for Potential Pharma Collaborations | AZN Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

astrazeneca announces total voting rights update for may 2025 By Investing.com - Investing.com India

Jun 02, 2025
pulisher
Jun 02, 2025

astrazeneca reports block listing interim review for share schemes - Investing.com

Jun 02, 2025
pulisher
Jun 02, 2025

astrazeneca reports block listing interim review for share schemes By Investing.com - Investing.com UK

Jun 02, 2025
pulisher
Jun 02, 2025

AstraZeneca Highlights Significant Gains Across Three Major Cancer Trials At ASCO - Benzinga

Jun 02, 2025
pulisher
Jun 02, 2025

AstraZeneca (AZN) Highlights Encouraging Enhertu Results in Breast Cancer Trial | AZN Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Breast Cancer Growth Slowed by 14 Months in New AstraZeneca Drug Study - Bloomberg

Jun 02, 2025
pulisher
Jun 02, 2025

AstraZeneca (AZN) Highlights Success in Breast Cancer Trial with Camizestrant | AZN Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

AstraZeneca: promising results for Imfinzi in gastric cancer - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

AstraZeneca: camizestrant effective in breast cancer - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

AstraZeneca Breast Cancer Pill Slows Disease by Over Six Months - Bloomberg.com

Jun 02, 2025
pulisher
Jun 02, 2025

AstraZeneca - Britannica

Jun 02, 2025
pulisher
Jun 02, 2025

AstraZeneca Pharma India Share Price Jumps Post Q4 Profit, Margin Growth - NDTV Profit

Jun 02, 2025
pulisher
Jun 01, 2025

ASCO: AstraZeneca Changes Management Of Breast Cancer Resistance With SERENA-6 - insights.citeline.com

Jun 01, 2025
pulisher
Jun 01, 2025

PRESS DIGEST- Financial TimesJune 2 - marketscreener.com

Jun 01, 2025
pulisher
Jun 01, 2025

AstraZeneca's (AZN) DATROWAY Shows Promise in Lung Cancer Trials - GuruFocus

Jun 01, 2025
pulisher
Jun 01, 2025

AstraZeneca's (AZN) DATROWAY Shows Promise in Lung Cancer Trials | AZN Stock News - GuruFocus

Jun 01, 2025
pulisher
Jun 01, 2025

AstraZeneca (AZN) Reports Positive Phase III Trial Results for IMFINZI | AZN Stock News - GuruFocus

Jun 01, 2025
pulisher
Jun 01, 2025

AstraZeneca (AZN) Reports Promising Phase III Trial Results for Camizestrant | AZN Stock News - GuruFocus

Jun 01, 2025
pulisher
Jun 01, 2025

AstraZeneca (AZN): ENHERTU Demonstrates Significant Survival Boo - GuruFocus

Jun 01, 2025
pulisher
Jun 01, 2025

AstraZeneca breast cancer medicine slows disease by over six months - The Economic Times

Jun 01, 2025
pulisher
Jun 01, 2025

Blood test-guided treatment with AstraZeneca pill cuts breast cancer progression risk - marketscreener.com

Jun 01, 2025
pulisher
Jun 01, 2025

A funding flashpoint, Pfizer’s $1B poster and AstraZeneca advertising - BioPharma Dive

Jun 01, 2025
pulisher
Jun 01, 2025

AstraZeneca drug could help keep a common breast cancer at bay - BioPharma Dive

Jun 01, 2025
pulisher
Jun 01, 2025

IMFINZI (Durvalumab) Regimen Reduced Risk Of Progression, Recurrence Or Death By 29% In Early-Stage Gastric Cancer Versus Chemotherapy Alone In Matterhorn Phase III Trial - marketscreener.com

Jun 01, 2025
pulisher
Jun 01, 2025

Blood test-guided treatment with AstraZeneca pill cut risk of breast cancer progression, study finds - marketscreener.com

Jun 01, 2025
pulisher
May 30, 2025

AstraZeneca Reaches $51 Million Settlement in Pay-for-Delay Suit - Bloomberg Law News

May 30, 2025
pulisher
May 30, 2025

AstraZeneca agrees to $51 million settlement in Seroquel antitrust class action - Reuters

May 30, 2025
pulisher
May 30, 2025

Danaher Partners With AstraZeneca to Support Precision Medicine - Yahoo Finance

May 30, 2025
pulisher
May 30, 2025

AstraZeneca, Danaher to Develop New Precision Medicine Diagnostic Tools - marketscreener.com

May 30, 2025
pulisher
May 30, 2025

Barclays Remains Upbeat on AstraZeneca, Expects US Conference to Highlight Breast Cancer Franchise - marketscreener.com

May 30, 2025
pulisher
May 30, 2025

AstraZeneca gets CDSCO nod for new indications of Benralizumab, Osimertinib in India - Medical Dialogues

May 30, 2025
pulisher
May 30, 2025

Danaher Corporation (DHR) Launches Partnership with AstraZeneca PLC (AZN) to Scale Next-Gen Precision Medicine Tests - Yahoo Finance

May 30, 2025
pulisher
May 29, 2025

AstraZeneca Inks $51.4M Settlement In Pay-For-Delay Case - Law360

May 29, 2025
pulisher
May 29, 2025

Danaher in partnership with AstraZeneca for diagnostic tests for precision medicine (DHR:NYSE) - Seeking Alpha

May 29, 2025
pulisher
May 29, 2025

Danaher partners with AstraZeneca on AI diagnostics By Investing.com - Investing.com Nigeria

May 29, 2025
pulisher
May 29, 2025

Bispecific Antibody Drug Conjugates Clinical Trials Bispecific ADC Market Size Insight - GlobeNewswire Inc.

May 29, 2025
pulisher
May 29, 2025

RNA Targeting Small Molecule Drug Discovery Research Report 2025 - GlobeNewswire Inc.

May 29, 2025
pulisher
May 28, 2025

Responsible care and use of animals in research - AstraZeneca

May 28, 2025
pulisher
May 28, 2025

Targeted Drug Delivery Research Business Analysis Report 2024-2030 with Focus on 30+ Key Players Such as AbbVie, Amgen, AstraZeneca, Becton Dickinson and Co, & Bristol-Myers Squibb - Yahoo Finance

May 28, 2025
pulisher
May 28, 2025

Eli Lilly vs. AstraZeneca: Which Pharma Powerhouse is the Better Buy? - Yahoo Finance

May 28, 2025
pulisher
May 28, 2025

Transcript : AstraZeneca PLCSpecial Call - marketscreener.com

May 28, 2025
pulisher
May 28, 2025

AstraZeneca and Global Transparency - AstraZeneca

May 28, 2025
pulisher
May 28, 2025

Ethics and Compliance - AstraZeneca

May 28, 2025
pulisher
May 28, 2025

Nature - AstraZeneca

May 28, 2025
pulisher
May 28, 2025

Inclusion and diversity - AstraZeneca

May 28, 2025
pulisher
May 28, 2025

Community investment - AstraZeneca

May 28, 2025
pulisher
May 28, 2025

Health Equity - AstraZeneca

May 28, 2025
pulisher
May 27, 2025

AstraZeneca (AZN) Collaborates on Major AI Infrastructure in Swe - GuruFocus

May 27, 2025
pulisher
May 27, 2025

AstraZeneca PLC (AZN) Trial: Airsupra Cuts Severe Asthma Risk by 47% - MSN

May 27, 2025
pulisher
May 27, 2025

AstraZeneca (AZN) Executive Joins Rapid Micro Biosystems' Board | AZN Stock News - GuruFocus

May 27, 2025
Kapitalisierung:     |  Volumen (24h):